OR2805

· OncoResponse, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OR2805, covering 2023-11-02 to 2023-11-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents [Phase 1, Phase 2]

See pricing